EA201990095A1 - КОНДЕНСИРОВАННЫЕ ТИОФЕНОВЫЕ ПРОИЗВОДНЫЕ, ПРИЕМЛЕМЫЕ В КАЧЕСТВЕ ИНГИБИТОРОВ NAPI-IIb - Google Patents

КОНДЕНСИРОВАННЫЕ ТИОФЕНОВЫЕ ПРОИЗВОДНЫЕ, ПРИЕМЛЕМЫЕ В КАЧЕСТВЕ ИНГИБИТОРОВ NAPI-IIb

Info

Publication number
EA201990095A1
EA201990095A1 EA201990095A EA201990095A EA201990095A1 EA 201990095 A1 EA201990095 A1 EA 201990095A1 EA 201990095 A EA201990095 A EA 201990095A EA 201990095 A EA201990095 A EA 201990095A EA 201990095 A1 EA201990095 A1 EA 201990095A1
Authority
EA
Eurasian Patent Office
Prior art keywords
napi
thiophene derivatives
condensed thiophene
derivatives acceptable
iib
Prior art date
Application number
EA201990095A
Other languages
English (en)
Other versions
EA037376B1 (ru
Inventor
Дэвид Эндрю Коатес
Кевин Роберт Фэйлс
Джеффри Алан Петерсон
Джеффри Майкл Шкерянтц
Цюаньжун ШЭНЬ
Мэттью Джон Вэлли
Джон Роули Веттерау II
Дариуш Станислав Водка
Янпин Сюй
Original Assignee
Эли Лилли Энд Компани
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Эли Лилли Энд Компани filed Critical Эли Лилли Энд Компани
Publication of EA201990095A1 publication Critical patent/EA201990095A1/ru
Publication of EA037376B1 publication Critical patent/EA037376B1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D333/52—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes
    • C07D333/62—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
    • C07D333/66—Nitrogen atoms not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4995—Pyrazines or piperazines forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08—Bridged systems

Abstract

Согласно данному изобретению предложены соединения формулыих фармацевтически приемлемые соли, фармацевтические композиции и способы применения этих соединений, солей или композиций для лечения гиперфосфатемии, хронической болезни почек и/или сердечно-сосудистого заболевания, связанного с хронической болезнью почек.
EA201990095A 2016-08-15 2017-08-08 Конденсированные тиофеновые производные, приемлемые в качестве ингибиторов napi-iib EA037376B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662375169P 2016-08-15 2016-08-15
PCT/US2017/045843 WO2018034883A1 (en) 2016-08-15 2017-08-08 Condensed thiophene derivatives useful as napi-iib inhibitors

Publications (2)

Publication Number Publication Date
EA201990095A1 true EA201990095A1 (ru) 2019-07-31
EA037376B1 EA037376B1 (ru) 2021-03-22

Family

ID=59677343

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201990095A EA037376B1 (ru) 2016-08-15 2017-08-08 Конденсированные тиофеновые производные, приемлемые в качестве ингибиторов napi-iib

Country Status (24)

Country Link
US (1) US10934280B2 (ru)
EP (1) EP3497091B1 (ru)
JP (1) JP6653410B2 (ru)
KR (1) KR102266143B1 (ru)
CN (1) CN109563070B (ru)
AU (1) AU2017312783B2 (ru)
BR (1) BR112019000929A2 (ru)
CA (1) CA3033628C (ru)
CY (1) CY1123576T1 (ru)
DK (1) DK3497091T3 (ru)
EA (1) EA037376B1 (ru)
ES (1) ES2830444T3 (ru)
HR (1) HRP20202025T1 (ru)
HU (1) HUE052351T2 (ru)
IL (1) IL264785B (ru)
LT (1) LT3497091T (ru)
MX (1) MX2019001781A (ru)
PL (1) PL3497091T3 (ru)
PT (1) PT3497091T (ru)
RS (1) RS61165B1 (ru)
SA (1) SA519401049B1 (ru)
SI (1) SI3497091T1 (ru)
WO (1) WO2018034883A1 (ru)
ZA (1) ZA201900305B (ru)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020102889A1 (en) * 2018-11-19 2020-05-28 Fouda Ahmed 4,5,6,7-tetrahydro-l-benzothiophene modulators of retinoic acid receptor related (rar) orphan nuclear receptors (rors)
JP7194848B2 (ja) * 2019-05-16 2022-12-22 イーライ リリー アンド カンパニー ナトリウム－水素交換体３阻害剤化合物
AR126060A1 (es) 2021-06-08 2023-09-06 Chugai Pharmaceutical Co Ltd Método para producir derivado de dihidropiridazin-3,5-diona
EP4353233A1 (en) 2021-06-08 2024-04-17 Chugai Seiyaku Kabushiki Kaisha Preparation containing dihydropyridazine-3,5-dione derivative
WO2023219127A1 (ja) * 2022-05-11 2023-11-16 中外製薬株式会社 嚢胞性疾患を治療または予防するための医薬組成物

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2011246072B2 (en) 2010-04-28 2014-06-26 Astellas Pharma Inc. Tetrahydrobenzothiophene compound
EA023955B1 (ru) 2011-10-27 2016-07-29 Астеллас Фарма Инк. Производное аминоалкилзамещенного n-тиенилбензамида
WO2014003153A1 (ja) 2012-06-28 2014-01-03 協和発酵キリン株式会社 置換アミド化合物
WO2016026372A1 (zh) * 2014-08-22 2016-02-25 江苏恒瑞医药股份有限公司 噻吩并环烷基或噻吩并杂环基类衍生物、其制备方法及其在医药上的应用

Also Published As

Publication number Publication date
WO2018034883A1 (en) 2018-02-22
RS61165B1 (sr) 2021-01-29
BR112019000929A2 (pt) 2019-07-09
LT3497091T (lt) 2020-12-28
IL264785B (en) 2021-04-29
KR102266143B1 (ko) 2021-06-17
AU2017312783A1 (en) 2019-01-24
PT3497091T (pt) 2020-11-30
MX2019001781A (es) 2019-07-04
JP6653410B2 (ja) 2020-02-26
HRP20202025T1 (hr) 2021-02-19
AU2017312783B2 (en) 2020-02-06
US20200031813A1 (en) 2020-01-30
SI3497091T1 (sl) 2020-11-30
ZA201900305B (en) 2020-12-23
CA3033628A1 (en) 2018-02-22
US10934280B2 (en) 2021-03-02
CN109563070B (zh) 2021-02-26
EP3497091B1 (en) 2020-10-07
EP3497091A1 (en) 2019-06-19
JP2019527734A (ja) 2019-10-03
EA037376B1 (ru) 2021-03-22
SA519401049B1 (ar) 2021-07-14
KR20190026895A (ko) 2019-03-13
DK3497091T3 (da) 2020-10-19
CA3033628C (en) 2021-01-12
NZ750153A (en) 2021-01-29
CN109563070A (zh) 2019-04-02
CY1123576T1 (el) 2022-03-24
ES2830444T3 (es) 2021-06-03
PL3497091T3 (pl) 2021-02-08
HUE052351T2 (hu) 2021-04-28

Similar Documents

Publication Publication Date Title
EA201790765A1 (ru) Производные спиродиамина в качестве ингибиторов альдостерон-синтазы
EA201891494A1 (ru) Гетероциклические соединения в качестве иммуномодуляторов
BR112017003054A2 (pt) compostos de aminopirimidinila como inibidores de jak
EA201892207A1 (ru) Индолкарбоксамидные соединения
EA201891063A1 (ru) Производные дигидроимидазопиразинона, применимые в лечении рака
EA201692079A1 (ru) Ингибиторы лизин-специфической деметилазы-1
EA201691134A1 (ru) Новые ингибиторы глутаминазы
EA201791420A1 (ru) Соединения триазолопиримидина и их применения
EA201791256A1 (ru) Производные хиназолина, применяемые для лечения вич
EA201650031A1 (ru) Производные пирролидин-2,5-диона, фармацевтические композиции и способы применения в качестве ингибиторов ido1
EA201691516A1 (ru) Дигидропирролопиридиновые ингибиторы ror-гамма
EA201990095A1 (ru) КОНДЕНСИРОВАННЫЕ ТИОФЕНОВЫЕ ПРОИЗВОДНЫЕ, ПРИЕМЛЕМЫЕ В КАЧЕСТВЕ ИНГИБИТОРОВ NAPI-IIb
EA201692487A1 (ru) Ингибиторы фосфатидилинозитол-3-киназы
EA201691421A1 (ru) Гетероарилы и их применение
EA201692268A1 (ru) Ингибиторы фосфатидилинозитол-3-киназы
EA201790085A1 (ru) Ингибиторы лизин-специфической деметилазы-1
EA201790745A1 (ru) Трициклические соединения
EA201692470A1 (ru) Фармацевтические комбинации
EA201791696A1 (ru) Композиция для лечения веноокклюзионной болезни печени
EA201790870A1 (ru) Трициклические атропоизомерные соединения
CY1122313T1 (el) Ορβεπιταντη για την αγωγη του χρονιου κνησμου
EA201691918A1 (ru) Фармацевтические составы ингибитора киназ семейства raf, способы их получения и способы их применения
EA201790156A1 (ru) Азетидинилоксифенилпирролидиновые соединения
EA201691566A1 (ru) Применение производных пиридазина для предупреждения или лечения атаксического синдрома
EA201890364A1 (ru) СОЕДИНЕНИЯ, ПРИГОДНЫЕ ДЛЯ ИНГИБИРОВАНИЯ ROR-ГАММА-t

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG TJ TM